Clinical Plenary #1

Nov 09 2025
Convention Center: Hall A (General Session), Concourse Level
11:30 AM - 12:30 PM
Live Streamed
Captured

World Class Speakers

Christopher L Bowlus, MD, FAASLD
Abstract Presenter

Christopher L Bowlus, MD, FAASLD

University of California, Davis
Nelia Hernandez, MD
Abstract Presenter

Nelia Hernandez, MD

Hospital de Clinicas, Universidad de la Republica
Heather Patton, MD, FAASLD
Abstract Presenter

Heather Patton, MD, FAASLD

VA San Diego Healthcare
Nelia Hernandez, MD
Moderator

Nelia Hernandez, MD

Hospital de Clinicas, Universidad de la Republica
Heather Patton, MD, FAASLD
Moderator

Heather Patton, MD, FAASLD

VA San Diego Healthcare

Journey Maps

Presentations

11:30 AM - 11:45 AM
May 19 2026
Washington, D.C.

Long-term data of elafibranor in primary sclerosing cholangitis: Interim safety and efficacy data from the ongoing open-label extension of the ELMWOOD phase II trial

Christopher L Bowlus, MD, FAASLD , Abstract Presenter
Cholestatic and Autoimmune
Cirrhosis and Portal Hypertension
Liver Cancer
11:45 AM - 12:00 PM
May 19 2026
Washington, D.C.

Left Ventricular Mass Index, a key metric for cirrhotic cardiomyopathy, is a better predictor of morbidity and mortality than PELD in pediatric cirrhosis

Nelia Hernandez, MD , Abstract Presenter
Cholestatic and Autoimmune
Cirrhosis and Portal Hypertension
Liver Cancer
12:00 PM - 12:15 PM
May 19 2026
Washington, D.C.

Efruxifermin was associated with improvements in multiple non-invasive tests indicative of fibrosis regression in participants with compensated cirrhosis due to MASH (SYMMETRY)

Heather Patton, MD, FAASLD , Abstract Presenter
Cholestatic and Autoimmune
Cirrhosis and Portal Hypertension
Liver Cancer